Universal Sequencing Technology (UST) was established 2015 by a group of NGS technology veterans and has locations in Canton, Massachusetts and Carlsbad, California. UST are dedicated to the development of the most advanced, cost-effective, long-read DNA sequencing technologies. Currently, Universal Sequencing Technology have filed a total of 23 patent applications covering linked, long-read library preparation chemistry and groundbreaking 3rd generation DNA sequencing technology.

Nucleus Biotech is pleased to offer UST´s TELL-Seq kit portfolio featuring single-tube Transposase Enzyme Linked Long-read Sequencing (TELL-seqTM) technology ( Chen et al., Genome Research, June 2020 ), which enables a low-cost, high-accuracy and high-throughput short-read second-generation sequencer to generate over 100 kb long-range sequencing information with as little as 0.1 ng input material.